Objective: To detect the plasma levels of mannan?binding lectin (MBL) and MBL?associated serine protease?2 (MASP-2) in patients with hepatocellular carcinoma (HCC) and explore their role in the tumorigenesis and progression of HCC.
Methods: The plasma levels of MBL and MASP?2 were detected by enzyme?linked immunosorbent assay in 64 HCC patients and 30 healthy control subjects. The correlation of MBL and MASP?2 with the clinical parameters of HCC patients were analyzed.
Results: The plasma levels of MBL (P=0.014) and MASP?2 (P=0.002) were significantly higher in HCC patients than in the healthy controls, but the MBL?to?MASP?2 ratio did not differ significantly between the two groups. In HCC patients, plasma MBL level was positively correlated with vascular invasion (r=0.253, P=0.047) and total bilirubin level (r=0.283, P=0.024). The plasma level of MASP?2 was positively correlated with TNM stage (r=0.276, P=0.027) and negatively correlated with plasma albumin level (r=0.?0.317, P=0.015). ROC curve analysis revealed an area under curve of 0.665 for MBL (P=0.010) and 0.694 for MASP?2 (P=0.003). The sensitivities of MBL and MASP?2 were 50% and 89.1% in the diagnosis of HCC, respectively.
Conclusion: MBL and MASP?2 are associated with the inflammatory state and disease progression in patients with HCC.
目的: 检测肝细胞肝癌患者血浆中甘露糖结合凝集素（MBL）、MBL相关丝氨酸蛋白酶-2（MASP-2）的表达水平，探讨其与肝细胞肝癌发生发展的相关性。
方法: 用酶联免疫吸附测定方法检测64例肝细胞肝癌患者及30例健康人血浆中MBL及MASP-2的表达水平，并用统计学方法分析患者血浆中MBL及MASP-2的浓度与各临床指标的相关性。
结果: 肝细胞肝癌患者血浆中MBL和MASP-2的浓度均显著高于健康人群（P=0.014、0.002），MBL/MASP-2比值在健康人群与肝细胞肝癌患者中的差异无统计学意义，此外，患者血浆中MBL与MASP-2并无相关性。在肝细胞肝癌患者中，血浆MBL水平与肿瘤的血管侵犯（r=0.253，P=0.047）和总胆红素水平（r=0.283，P=0.024）呈正相关；血浆中MASP-2水平与肝细胞肝癌的TNM分期呈正相关（r=0.276，P=0.027），而与血浆白蛋白呈负相关（r=0.-0.317，P=0.015）。经ROC曲线分析，MBL和MASP-2曲线下面积分别为0.665（P=0.010）和0.694（P=0.003），对肝细胞肝癌诊断的敏感性分别为50%和89.1%。
结论: 补体凝集素途径的关键分子MBL、MASP-2与肝细胞肝癌患者的炎症状态和疾病进展相关，参与了肝癌的发生与发展。